How has Dianthus Therapeutics's proceeds from warrant exercises changed year-over-year?

Dianthus Therapeutics's proceeds from warrant exercises decreased by 0.0% year-over-year, from $1K to $1K.

Dianthus Therapeutics DNTH Proceeds From Warrant Exercises

ImmunityBio, Inc.IBRX

$53.54M—

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Market cap$4.51B+662%

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Dianthus Therapeutics's proceeds from warrant exercises?: Dianthus Therapeutics (DNTH) reported proceeds from warrant exercises of $1K in Q1 2026.
How has Dianthus Therapeutics's proceeds from warrant exercises changed year-over-year?: Dianthus Therapeutics's proceeds from warrant exercises decreased by 0.0% year-over-year, from $1K to $1K.